Sitagliptin: here's the fair price
This is what US pharmacies pay, on average, for sitagliptin. Use it to spot a fair cash price, and feel good about asking for one.
Sitagliptin Phosphate-Metformin 50 Mg-1,000 Mg Tablet
A fair cash price is usually this cost plus a dispensing fee. If your quote is many times higher, ask about a generic, another pharmacy, or a cash discount.
Ask for generic Sitagliptin Phosphate-Metformin 50 Mg-1,000 Mg Tablet. Pharmacies pay about $75.28 for 30. Ask your pharmacy for its cash price and compare it with your copay. A fair cash price is close to this cost plus a dispensing fee.
Source: CMS NADAC as of 2026-11-04. Ask your prescriber or pharmacist whether a generic is right for you.
Source: CMS NADAC weekly file as of 2026-11-04. Median across NDCs with the same description. Public domain.
Your ZIP and location stay in your browser. We never store them.
Every strength and form
| Product | Pharmacy cost | 30 count | Effective |
|---|---|---|---|
| SITAGLIPTIN PHOSPHATE-METFORMIN 50 MG-1,000 MG TABLETGeneric | $2.51 per tablet or capsule | $75.28 | 10/21/2026 |
| SITAGLIPTIN PHOSPHATE-METFORMIN 50 MG-500 MG TABLETGeneric | $2.51 per tablet or capsule | $75.44 | 10/21/2026 |
| SITAGLIPTIN PHOSPHATE 25 MG TABLETGeneric | $3.61 per tablet or capsule | $108.35 | 10/21/2026 |
| SITAGLIPTIN PHOSPHATE 50 MG TABLETGeneric | $3.72 per tablet or capsule | $111.50 | 10/21/2026 |
| SITAGLIPTIN PHOSPHATE-METFORMIN ER 50 MG-500 MG TABLETGeneric | $3.74 per tablet or capsule | $112.19 | 10/21/2026 |
| SITAGLIPTIN PHOSPHATE 100 MG TABLETGeneric | $3.85 per tablet or capsule | $115.48 | 10/21/2026 |
| SITAGLIPTIN PHOSPHATE-METFORMIN ER 50 MG-1,000 MG TABLETGeneric | $4.18 per tablet or capsule | $125.34 | 10/21/2026 |
| SITAGLIPTIN PHOSPHATE-METFORMIN ER 100 MG-1,000 MG TABLETGeneric | $8.34 per tablet or capsule | $250.28 | 10/21/2026 |
Source: CMS NADAC, as of 2026-11-04. National average acquisition cost, not a retail quote.
Label basics
What it is used for (FDA label)
1 INDICATIONS AND USAGE JANUVIA ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: JANUVIA should not be used in patients with type 1 diabetes ( 1 ) JANUVIA has not been studied in patients with a history of pancreatitis. ( 1 , 5.1 ) Limitations of Use JANUVIA should not be used in patients with type 1 diabetes. JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of...
Common side effects (FDA label)
6 ADVERSE REACTIONS The following adverse reactions are also discussed elsewhere in the labeling: Pancreatitis [see Warnings and Precautions (5.1) ] Heart Failure [see Warnings and Precautions (5.2) ] Acute Renal Failure [see Warnings and Precautions (5.3) ] Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues [see Warnings and Precautions (5.4) ] Hypersensitivity Reactions [see Warnings and Precautions (5.5) ] Severe and Disabling Arthralgia [see Warnings and Precautions (5.6) ] Bullous Pemphigoid [see Warnings and Precautions (5.7) ] Adverse reactions reported in ≥5% of...
Drug interactions (from the label)
7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4) .]
Warnings (from the label)
5 WARNINGS AND PRECAUTIONS Pancreatitis: There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. If pancreatitis is suspected, promptly discontinue JANUVIA. ( 5.1 ) Heart failure : Heart failure has been observed with two other members of the DPP-4 inhibitor class. Consider risks and benefits of JANUVIA in patients who have known risk factors for heart failure. Monitor patients for signs and symptoms. ( 5.2 ) Acute Renal Failure: Has been reported postmarketing, sometimes requiring dialysis. Assessment of renal function is recommended prior to initiating JANUVIA and periodically thereafter. ( 5.3 ) Hypoglycemia with...
Source: FDA drug label via openFDA, label effective 2026-07-08. Full label on DailyMed. Excerpts are verbatim and truncated. Read the full label and ask your pharmacist.